TR201708567T4 - Sigma ligandların kemik kanseri ağrısında kullanımı. - Google Patents
Sigma ligandların kemik kanseri ağrısında kullanımı. Download PDFInfo
- Publication number
- TR201708567T4 TR201708567T4 TR2017/08567T TR201708567T TR201708567T4 TR 201708567 T4 TR201708567 T4 TR 201708567T4 TR 2017/08567 T TR2017/08567 T TR 2017/08567T TR 201708567 T TR201708567 T TR 201708567T TR 201708567 T4 TR201708567 T4 TR 201708567T4
- Authority
- TR
- Turkey
- Prior art keywords
- bone cancer
- cancer pain
- sigma ligands
- sigma
- ligands
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 3
- 206010005949 Bone cancer Diseases 0.000 title abstract 2
- 208000018084 Bone neoplasm Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compression, Expansion, Code Conversion, And Decoders (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Buluş, kemik kanseri ile bağlantılı ağrıyı önlemek ve/veya tedavi etmek için bir sigma ligandın, özellikle formül (I)'e sahip bir sigma ligandın kullanımı ile ilgilidir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382330A EP2460519A1 (en) | 2010-12-03 | 2010-12-03 | Use of sigma ligands in bone cancer pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201708567T4 true TR201708567T4 (tr) | 2019-01-21 |
Family
ID=43629676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2017/08567T TR201708567T4 (tr) | 2010-12-03 | 2011-12-02 | Sigma ligandların kemik kanseri ağrısında kullanımı. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20130324535A1 (tr) |
| EP (2) | EP2460519A1 (tr) |
| JP (1) | JP6027014B2 (tr) |
| KR (1) | KR101855358B1 (tr) |
| CN (1) | CN103313709B (tr) |
| AR (1) | AR084730A1 (tr) |
| BR (1) | BR112013013369A8 (tr) |
| CA (1) | CA2819442C (tr) |
| CO (1) | CO6781549A2 (tr) |
| CY (1) | CY1119030T1 (tr) |
| DK (1) | DK2646025T3 (tr) |
| ES (1) | ES2626672T3 (tr) |
| HR (1) | HRP20170818T1 (tr) |
| HU (1) | HUE033488T2 (tr) |
| IL (1) | IL226706A (tr) |
| LT (1) | LT2646025T (tr) |
| MA (1) | MA34878B1 (tr) |
| ME (1) | ME02852B (tr) |
| MX (1) | MX343773B (tr) |
| MY (1) | MY171994A (tr) |
| NZ (1) | NZ612119A (tr) |
| PL (1) | PL2646025T3 (tr) |
| PT (1) | PT2646025T (tr) |
| RS (1) | RS56081B1 (tr) |
| RU (1) | RU2585095C2 (tr) |
| SG (1) | SG190745A1 (tr) |
| SI (1) | SI2646025T1 (tr) |
| TN (1) | TN2013000227A1 (tr) |
| TR (1) | TR201708567T4 (tr) |
| TW (1) | TWI629060B (tr) |
| UA (1) | UA112638C2 (tr) |
| WO (1) | WO2012072782A1 (tr) |
| ZA (1) | ZA201304966B (tr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| EP2818166A1 (en) * | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
| JP2016530322A (ja) * | 2013-09-12 | 2016-09-29 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | Ｎｓａｉｄおよびシグマレセプターリガンドの組み合わせ |
| CA2933057A1 (en) | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and sigma receptor ligands combinations |
| CN105873578A (zh) | 2013-12-17 | 2016-08-17 | 埃斯蒂维实验室股份有限公司 | 血清素－去甲肾上腺素再摄取抑制剂(SNRIs)和σ受体配体组合物 |
| EP2929883A1 (en) * | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors |
| TW201806601A (zh) * | 2016-07-12 | 2018-03-01 | 以斯提夫博士實驗室股份有限公司 | σ受體配體在皰疹後遺疼痛中的用途 |
| CN112165955A (zh) * | 2018-05-21 | 2021-01-01 | 益普生生物制药有限公司 | 抑制骨癌引起的异常性疼痛 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN112341397B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 吡嗪类衍生物或盐、异构体、其制备方法及用途 |
| KR20210151572A (ko) | 2020-06-05 | 2021-12-14 | 주식회사 허밍아비스 | 발열체 조성물 및 이를 이용한 마스크 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI452035B (zh) * | 2003-06-26 | 2014-09-11 | Novartis Ag | 以５員雜環為主之ｐ３８激酶抑制劑 |
| AU2005276590B2 (en) * | 2004-08-27 | 2011-05-19 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| RU2417987C2 (ru) * | 2004-08-27 | 2011-05-10 | Лабораторьос Дель Др.Эстеве, С.А. | Ингибиторы сигма-рецептора |
| MX2008011016A (es) * | 2006-03-01 | 2008-09-08 | Esteve Labor Dr | Inhibidores de receptor sigma. |
| EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
-
2010
- 2010-12-03 EP EP10382330A patent/EP2460519A1/en not_active Withdrawn
-
2011
- 2011-02-12 UA UAA201308348A patent/UA112638C2/uk unknown
- 2011-11-25 TW TW100143323A patent/TWI629060B/zh not_active IP Right Cessation
- 2011-12-02 LT LTEP11794082.5T patent/LT2646025T/lt unknown
- 2011-12-02 US US13/991,282 patent/US20130324535A1/en not_active Abandoned
- 2011-12-02 SI SI201131191A patent/SI2646025T1/sl unknown
- 2011-12-02 WO PCT/EP2011/071584 patent/WO2012072782A1/en active Application Filing
- 2011-12-02 MA MA36072A patent/MA34878B1/fr unknown
- 2011-12-02 DK DK11794082.5T patent/DK2646025T3/en active
- 2011-12-02 MY MYPI2013001961A patent/MY171994A/en unknown
- 2011-12-02 CN CN201180065232.XA patent/CN103313709B/zh not_active Expired - Fee Related
- 2011-12-02 CA CA2819442A patent/CA2819442C/en not_active Expired - Fee Related
- 2011-12-02 NZ NZ612119A patent/NZ612119A/en not_active IP Right Cessation
- 2011-12-02 KR KR1020137017344A patent/KR101855358B1/ko active IP Right Grant
- 2011-12-02 ES ES11794082.5T patent/ES2626672T3/es active Active
- 2011-12-02 MX MX2013006140A patent/MX343773B/es active IP Right Grant
- 2011-12-02 TR TR2017/08567T patent/TR201708567T4/tr unknown
- 2011-12-02 AR ARP110104502A patent/AR084730A1/es unknown
- 2011-12-02 HU HUE11794082A patent/HUE033488T2/en unknown
- 2011-12-02 PT PT117940825T patent/PT2646025T/pt unknown
- 2011-12-02 SG SG2013042569A patent/SG190745A1/en unknown
- 2011-12-02 ME MEP-2017-120A patent/ME02852B/me unknown
- 2011-12-02 RU RU2013130222/15A patent/RU2585095C2/ru not_active IP Right Cessation
- 2011-12-02 BR BR112013013369A patent/BR112013013369A8/pt not_active Application Discontinuation
- 2011-12-02 JP JP2013541369A patent/JP6027014B2/ja not_active Expired - Fee Related
- 2011-12-02 RS RS20170575A patent/RS56081B1/sr unknown
- 2011-12-02 EP EP11794082.5A patent/EP2646025B1/en active Active
- 2011-12-02 PL PL11794082T patent/PL2646025T3/pl unknown
-
2013
- 2013-05-29 TN TNP2013000227A patent/TN2013000227A1/fr unknown
- 2013-06-03 IL IL226706A patent/IL226706A/en active IP Right Grant
- 2013-07-02 CO CO13155721A patent/CO6781549A2/es not_active Application Discontinuation
- 2013-07-03 ZA ZA2013/04966A patent/ZA201304966B/en unknown
-
2017
- 2017-05-30 HR HRP20170818TT patent/HRP20170818T1/hr unknown
- 2017-06-08 CY CY20171100604T patent/CY1119030T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201708567T4 (tr) | Sigma ligandların kemik kanseri ağrısında kullanımı. | |
| TR201903981T4 (tr) | Kanser tedavisi için bileşikler. | |
| CY1120102T1 (el) | Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CO6680628A2 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| EA200970737A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| MX2014009751A (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| NI201200175A (es) | Métodos de tratamiento de cáncer de vejiga | |
| PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| UA111148C2 (uk) | Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IN2014DN09228A (tr) | ||
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| TR201909522T4 (tr) | Anti-tümör aktivitesine sahip bir nonapeptit. | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| CR20140367A (es) | Inhibidores de iap | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
| DK2155179T3 (da) | Axomadol til smertebehandling arthrose | |
| MX2011006532A (es) | Compuestos anticancerigenos. |